Published in Healthcare Finance, Tax and Law Weekly, June 14th, 2006
Study 1: Angiogenesis is impaired by rosiglitazone's effects on endothelial cells.
"Rosiglitazone, an insulin sensitizer, is known to offer beneficial effects in retarding atherosclerotic vascular diseases. Since proliferation and angiogenesis are involved in initiation and plaque instability, two critical steps in the cardiovascular events, this study was designed to evaluate the mechanisms of rosiglitazone on endothelial proliferation and angiogenesis," researchers in Taiwan report.
"Rosiglitazone-treated human umbilical vein...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly